Characterization of P2X7 Purinergic Receptors and Their Function in Rat Lacrimal Gland

Robin R. Hodges, Joanna Vrouvlianis, Marie A. Shatos, and Darlene A. Dartt

PURPOSE. To characterize the effects of P2X7 purinergic receptors on lacrimal gland function.

METHODS. P2X7 purinergic receptors were identified by RT-PCR, Western blot analysis, and immunofluorescence techniques. Rat lacrimal gland acini were isolated by collagenase digestion. Acini were incubated with the fluorescent indicator molecule fura 2, and [Ca^{2+}]], was measured by a fluorescence imaging system. Protein secretion was measured with a fluorescence assay system. Activation of ERK 1/2 was determined by Western blot analysis with an antibody against phosphorylated (active) ERK 1/2.

RESULTS. P2X7 receptors were present in the lacrimal gland by RT-PCR and Western blot analysis. These receptors were located in the membranes of acinar and ductal cells and the cytoplasm of acinar cells. Activation of P2X7 receptors, with (benzoylbenzoyl)adenosine 5'-triphosphate increased [Ca^{2+}]], peroxidase secretion, and ERK 1/2 activation, each of which was inhibited by the P2X7 receptor inhibitors Brilliant Blue G or A 438079.

CONCLUSIONS. P2X7 purinergic receptors are present in rat lacrimal gland and when stimulated increase [Ca^{2+}]], protein secretion, and ERK 1/2 activation. (Invest Ophthalmol Vis Sci. 2009;50:5681–5689) DOI:10.1167/iovs.09-3670

The lacrimal gland is a tubuloacinergic exocrine gland that is responsible for secretion of the aqueous portion of the tear film.1 The aqueous portion consists of water, proteins, and electrolytes. Regulation of secretion is under neural control. Activation of the sensory nerves in the cornea and conjunctiva initiates an afferent pathway leading to the central nervous system. This, in turn, activates an efferent pathway to stimulate parasympathetic and sympathetic nerves that innervate the lacrimal gland.1

The functional unit of the lacrimal gland is the acinus structure, which consists of polarized cells connected around a central lumen via tight junctions. Receptors for neurotransmitters are present on the basolateral membranes. When these receptors are stimulated, they activate signal transduction pathways to stimulate protein secretion across the apical membrane and into small ducts.1 Epithelial cells line the ducts and modify the primary fluid. The small ducts coalesce to larger ducts and eventually into the main excretory duct, which empties onto the ocular surface. In addition to acinar and ductal cells, the third major cell type in the lacrimal gland is myoepithelial cells. These are large stellate-shaped cells that surround the acini and are believed to contract to help expel secretory products from the acinar cells, as occurs in the mammary gland.

We have previously identified several major pathways activated by nerves that cause protein secretion. Parasympathetic and sympathetic nerves are major stimuli of protein secretion. Acetylcholine, released from parasympathetic nerves, binds to the M3 muscarinic receptor to initiate secretion via the hydrolysis of phosphoinositols bisphosphate into 1,4,5 inositol trisphosphate (IP_{3})/Ca^{2+} and diacylglycerol (DAG)/protein kinase C (PKC) pathways.2–4

In addition to stimulating protein secretion, cholinergic agonists also activate another pathway which attenuates protein secretion, namely the extracellular signal-related kinase 1/2 (ERK 1/2, otherwise known as p42/p44 mitogen-activated protein kinase [MAPK]) pathway. Cholinergic agonists activate this pathway through the stimulation of nonreceptor tyrosine kinases Pyk2 and csrc. This initiates the Ras/Ral/MEK kinase pathway, which culminates in the activation of ERK 1/2.5,6

Sympathetic nerves release the neurotransmitter norepinephrine to activate α1-adrenergic receptors. These receptors stimulate endothelial nitric oxide synthase to activate guanylate cyclase, which increases the intracellular concentrations of cGMP. cGMP leads to the stimulation of protein secretion. In addition, these receptors transactivate the EGFR receptor to induce the ERK1/2 signaling cascade, which attenuates secretion.7

Purinergic receptors are identified by their ability to bind purines. This class of receptors has been divided into two major types, P1 and P2. P1 receptors are classic G protein-coupled receptors (GPCRs). P2 receptors are further subdivided into two groups, P2X and P2Y. P2X receptors are ATP-gated nonselective ion-gated channels, whereas P2Y receptors are GPCRs.8 Seven P2X receptors (P2X1–P2X7) and at least 12 P2Y receptors have been cloned to date.

P2X7 receptors are closely related receptors containing two transmembrane regions with a large extracellular domain with multiple glycosylation sites. P2X7 receptors have a larger intracellular domain than P2X1–6, and though P2X1–6 can be activated by low concentrations of ATP (EC_{50} 1–10 μM), P2X7 receptors require much higher concentrations of ATP to be activated (EC_{50} 300 μM).9 In addition, P2X7 receptors have a unique characteristic that aids in identification of this receptor in tissues. First, the response of P2X7 receptors is enhanced in the absence of Mg^{2+}. In macrophages and microglia, prolonged P2X7 agonist application can also lead to membrane blebbing and microvesiculation that is accompanied by IL-1β secretion and could contribute to an inflammatory response.10,11 In many cases, prolonged activation of P2X7 receptors and pores leads to cell death by necrosis or apoptosis.

We hypothesize that P2X7 receptor stimulation plays a significant role in the normal function of the lacrimal gland. To test this hypothesis, we sought to determine whether P2X7 receptors are present in the rat lacrimal gland, whether activation of P2X7 receptors plays a role in protein secretion, and whether activation of P2X7 receptors increases [Ca^{2+}]].

Reference

From the Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

Supported by National Institutes of Health Grant EY06177.

Submitted for publication March 5, 2009; revised June 2, 2009; accepted September 14, 2009.

Disclosure: R.R. Hodges, None; J. Vrouvlianis, None; M.A. Shatos, None; D.A. Dartt, None

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Corresponding author: Robin R. Hodges, Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, 20 Stanford Street, Boston, MA 02114; robin.hodges@schepens.harvard.edu.
MATERIALS AND METHODS

Materials

P2X7 rabbit polyclonal antibody and the control peptide were purchased from Alomone Laboratories (Jerusalem, Israel). Monoclonal antibodies directed against ERK 1/2 phosphorylated on Tyr202/204 (activated ERK), total ERK2, and mouse secondary antibody conjugated to horseradish peroxidase (HRP) were from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit secondary antibody conjugated to HRP was purchased from Millipore (Billerica, MA), whereas mouse secondary antibody conjugated to Cy2 was from Vector Laboratories (Burlingame, CA). Phallolidin conjugated to rhodamine was purchased from Sigma Chemical (St. Louis, MO). 3-[4-(2,3-Dichlorophenyl)-1H-tetrazol-1-yl]methyl]pyridine hydrochloride (A 438079) was from Tocris Bioscience (Ellisville, MI). Fura-2 AM and reagents (Amplex red, TRITol) were from Invitrogen (Carlsbad, CA). Reverse transcription system and PCR products were purchased from Promega (Madison, WI). Primers to G3DPH were purchased from Clonetics (Mountain View, CA). Collagenase (CLSIII) was purchased from Worthington Biochemicals (Lakewood, NJ). All other reagents were from Sigma Chemical.

Animals

All experiments were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Schepens Eye Research Institute Animal Care and Use Committee. Male Sprague-Dawley rats (125–150 g) were purchased from Taconic Farms (Germantown, NY). They were maintained in constant-temperature rooms with fixed light-dark intervals of 12 hours and were fed ad libitum. The rats were anesthetized for 1 minute in CO2 and decapitated. Both exorbital lacrimal glands were removed.

RT-PCR

The lacrimal gland was removed and homogenized in reagent (TRIzol; Invitrogen), and total RNA was isolated according to the manufacturer’s instructions. RNA was also isolated from rat brain to use as a positive control because P2X7 receptors are known to be present in this tissue.12 One microgram of purified total RNA was used for complementary DNA (cDNA) synthesis using the reverse transcription system (cDNA was amplified by the polymerase chain reaction (PCR) using primers specific to either P2X7 receptors or G3DPH in a thermal cycler (PCR Sprint; Thermolyhaid, Ashton, UK). The primers used for P2X7 were derived from previously published sequences13 (antisense, GTGCCATCTTGACCGAGGTGTATAAA; sense, GCCACCTCTGTA-AAGTTCCTCAGCAT). The PCR reaction consisted of 0.5 μM sense and antisense primers, 200 μM each dNTP, 1.5 μM MgCl₂, 1.25 U Taq polymerase, and 1 μL cDNA. The cycling conditions were 5 minutes hot start at 94°C, 40 cycles of denaturation for 1 minute at 94°C, annealing for 1 minute at 59°C, and extension for 1 minute at 72°C and a final extension at 72°C for 5 minutes. Samples with no cDNA served as the negative controls, whereas the presence of RNA for the housekeeping gene G3DPH was used as a positive control. After amplification, the products were separated by electrophoresis on a 1.5% agarose gel and visualized by ethidium bromide staining.

Western Blot Analysis

The presence of the P2X7 receptor in lacrimal gland was determined by Western blot analysis. The gland was homogenized in RIPA buffer containing 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% deoxycholic acid, 1% Triton X-100, 0.1% SDS, and 1 mM EDTA containing protease inhibitors (phenylmethylsulfonyl fluoride 100 μM/mL, aprotinin 30 μL/mL) and 100 mM sodium orthovanadate. Homogenized cells were sonicated and centrifuged at 20,000 g for 15 minutes at 4°C. Proteins in the supernatant were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on a 10% gel and transferred to nitrocellulose membranes. Nitrocellulose membranes were blocked overnight at 4°C in 5% nonfat dried milk in buffer containing 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 0.05% Tween-20 and then were incubated with the P2X7 antibody (1:300 dilution) for 1 hour at room temperature or overnight at 4°C, followed by incubation with HRP-conjugated secondary antibody (1:5000 dilution). For preabsorption control, the P2X7 antibody was preincubated with the control peptide at 1:10 fold excess overnight before it was applied to the Western blot overnight and incubation with the secondary antibody.

Immunohistochemistry

Lacrimal glands were fixed in 4% formaldehyde diluted in phosphate-buffered saline (PBS; 145 mM NaCl, 7.3 mM Na₂HPO₄, and 2.7 mM NaH₂PO₄ [pH 7.2]) for 4 hours at 4°C. The tissue was then preserved in 30% sucrose in PBS at 4°C overnight, followed by embedding in optimal cutting temperature compound. Six-micron sections were cut, placed on slides, and air dried for 2 hours. The sections were rinsed for 5 minutes in PBS, and nonspecific sites were blocked by incubation with 10% normal goat serum, 1% bovine serum albumin, and 0.2% Triton X-100 in PBS for 45 minutes at room temperature. Sections were then incubated with the P2X7 primary antibody (1:200 dilution) for 2 hours at room temperature in a humidified chamber. The secondary antibody conjugated to Cy2 (1:150 dilution) was applied for 1 hour at room temperature. Phallolidin conjugated to rhodamine was used at 1:1000 dilution and added with the Cy2 secondary antibody. Coverslips were mounted with a medium consisting of glycerol and para-phenylenediamine. Preabsorption control was performed by incubation with P2X7 antibody preincubated with a control peptide at 1:10 fold excess overnight.
ing the P2X<sub>7</sub> antibody with a 10-fold excess of the control peptide at 4°C overnight before the solution was applied to the lacrimal gland section for 2 hours at room temperature. Sections incubated in the absence of primary antibody also served as a negative control. The sections were viewed by microscopy (Eclipse E80i; Nikon, Tokyo, Japan), and micrographs were taken with a digital camera (Spot; Diagnostic Instruments, Inc., Sterling Heights, MI).

**Preparation of Lacrimal Gland Acini**

Acini were prepared by collagenase digestion. In brief, lacrimal glands were trimmed and fragmented before incubation with collagenase CLSIII (100 U/mL) in Krebs-Ringer bicarbonate (KRB) buffer (119 mM NaCl, 4.8 mM KCl, 1.2 mM CaCl<sub>2</sub>, 1.2 mM MgSO<sub>4</sub>, 25 mM NaHCO<sub>3</sub>, 10 mM HEPES, and 5.5 mM glucose [pH 7.45]) and 0.5% BSA. Acini were prepared by collagenase digestion. In brief, lacrimal glands were trimmed and fragmented before incubation with collagenase CLSIII (100 U/mL) in Krebs-Ringer bicarbonate (KRB) buffer (119 mM NaCl, 4.8 mM KCl, 1.2 mM CaCl<sub>2</sub>, 1.2 mM MgSO<sub>4</sub>, 25 mM NaHCO<sub>3</sub>, 10 mM HEPES, and 5.5 mM glucose [pH 7.45]) and 0.5% BSA at 37°C. Fragments were subjected to pipetting through tips of decreasing diameter, filtered through nylon mesh (150-μm pore size), and centrifuged briefly (50g, 2 minutes). The pellet was washed twice with a 4% BSA solution in KRB buffer. The dispersed acini were allowed to recover for 60 minutes at 37°C before use.

**Measurement of [Ca<sup>2+</sup>]<sub>i</sub>**

Acini were incubated for 30 minutes at room temperature in the dark with KRB-HEPES containing 0.5% BSA, 0.5 μM fura 2 tetra-acetoxymethyl ester, 8 μM pluronic acid F127, and 250 μM sulfipyrazone. The cells were washed in KRB buffer containing 250 μM sulfipyrazone. Calcium measurements were obtained with a ratio imaging system (InCyt Im2; Intracellular Imaging, Cincinnati, OH) using excitation wavelengths of 340 and 380 nm and an emission wavelength of 505 nm. At least 10 acini clumps were selected for each condition. The experiments were then repeated for cells from at least three animals. 2′(3′)O-(4-Benzoylbenzoyl)adenosine 5′-triphosphate (BzATP), a P2X<sub>7</sub> receptor agonist, or the muscarinic receptor agonist carbachol (Cch), which binds to actin. (Inset) Phalloidin conjugated to rhodamine, which binds to actin. (C) Merged image of P2X<sub>7</sub> purinergic receptors (green) and phalloidin (red). Yellow: overlap between the two proteins. (D) Lacrimal gland sections were incubated with P2X<sub>7</sub>-antibody and the control peptide. Micrographs are from a single animal and are representative of three individual animals. Original magnifications, ×200; (Inset) ×400.

**Measurement of Peroxidase Secretion**

After the recovery period, acini were incubated in KRB buffer containing 0.5% BSA for 40 minutes at 37°C in the presence of BzATP or Cch. Inhibitors were added 20 minutes before BzATP. After a brief centrifugation, the supernatant was collected and the pellet was homogenized in 10 mM Tris HCl, pH 7.5. Peroxidase activity, an index of protein secretion, was measured in duplicate in both the supernatant and the pellet. Peroxidase was measured using a reagent (Amplex Red; Invitrogen), which, when oxidized by peroxidase in the presence of hydrogen peroxide, produces a highly fluorescent molecule. The amount of fluorescence in the supernatant and pellet was quantified on a fluorescence microplate reader (model FL600; Bio-Tek, Winooski, VT) with an excitation wavelength of 530 nm and an emission wavelength of 590 nm. Peroxidase was expressed as a percentage of peroxidase secreted into the media (supernatant) compared with total peroxidase present in the cells (pellet + supernatant). Data are expressed as fold increase × basal, which was set as 1.

**Measurement of ERK 1/2 Activity**

Activation of ERK 1/2 was measured by Western blot analysis. Acini were incubated with BzATP or Cch for 10 minutes in KRB buffer. Inhibitors were added 20 minutes before BzATP. Reaction was terminated by brief centrifugation. The pellet was resuspended in RIPA buffer and analyzed by Western blot on a 10% polyacrylamide gel, as described, using an antibody for total ERK (ERK2, 1:1000) or phosphorylated (activated) ERK 1 and 2 (1:500 dilution) overnight at 4°C. The secondary antibody (1:2000) was added for 30 minutes at room temperature. Films were scanned, and data were analyzed using ImageJ software (developed by Wayne Rasband, National Institutes of Health, Bethesda, MD; available at http://rsb.info.nih.gov/ij/index.html). Values for phosphorylated enzymes (amounts for ERK 1 and 2 were scanned together) were normalized to the amount of total enzyme using antibodies to nonphosphorylated enzyme, and were expressed as fold times basal, which was set as 1. This is described previously.\(^5,6,14\)
Data Presentation and Statistical Analysis

Data are expressed as the fold increase over the basal value, which was standardized to 1.0. Results are expressed as the mean ± SEM. Data were analyzed by Student’s t-test. P < 0.05 was considered statistically significant.

RESULTS

Identification of P2X7 Receptors in the Lacrimal Gland

To determine whether P2X7 receptors are present in the rat lacrimal gland, RT-PCR was performed on RNA isolated from rat lacrimal gland with primers specific to P2X7 and the housekeeping gene G3DPH. As shown in Figure 1A, a PCR product at the expected size of 354 bp for P2X7 receptor and a band of 452 bp for G3DPH were present in both brain and lacrimal gland.

To ensure that the P2X7 protein is expressed in the lacrimal gland, proteins in lysates from brain and lacrimal gland were separated by electrophoresis and subjected to Western blot analysis using an antibody specific to P2X7 receptors. Both the brain and the lacrimal gland contained proteins at 69 kDa, the calculated molecular weight of the P2X7 receptor (Fig. 1B). Incubation of the primary antibody with the control peptide eliminated the bands in both brain and lacrimal gland (Fig. 1B).

The location of P2X7 receptors in the lacrimal gland was then determined. Lacrimal gland sections were incubated with the same P2X7 receptor antibody used for Western blot experiments (Fig. 2A) and phalloidin conjugated to rhodamine.
which binds to actin (Fig. 2B). P2X<sub>7</sub> receptors were present at or near the apical and basolateral membranes of virtually all acinar cells and ductal cells, similar to the location of actin (Fig. 2G; P2X<sub>7</sub> shown in green, phalloidin shown in red). In addition, P2X<sub>7</sub> receptors were also present in the cytosol of acinar cells. Incubation with the peptide to which the P2X<sub>7</sub> antibody was generated abolished the staining (Fig. 2D). These experiments demonstrate that P2X<sub>7</sub> receptors are present in rat lacrimal gland.

**Effect of Activation of P2X<sub>7</sub> Receptors on Intracellular [Ca<sup>2+</sup>]**

Given that P2X receptors are nonselective ion channels, measurement of [Ca<sup>2+</sup>] is a useful tool to determine the activation of these receptors. Using the P2X<sub>7</sub> receptor agonist BzATP, we determined whether these receptors are functional in rat lacrimal gland. Lacrimal gland acini were isolated and incubated with fura 2, as described previously, and P2X<sub>7</sub> antagonists were added for the last 20 minutes of fura 2 incubation. The first antagonist used was Brilliant Blue G (BBG), which is a selective inhibitor for P2X<sub>7</sub> receptors. After preincubation with BBG (10<sup>-5</sup> M), the cells were then stimulated with BzATP 10<sup>-5</sup> M in Mg<sup>2+</sup>-free buffer, and [Ca<sup>2+</sup>] was measured. The Ca<sup>2+</sup> trace of the mean of three experiments is shown in Figure 4A, indicating that BBG 10<sup>-5</sup> M partially inhibited [Ca<sup>2+</sup>]<sub>i</sub>, stimulated by BzATP 10<sup>-5</sup> M, whereas BBG 10<sup>-5</sup> M completely inhibited this response. When three independent experiments were analyzed for peak [Ca<sup>2+</sup>]<sub>i</sub>, BzATP 10<sup>-5</sup> M increased [Ca<sup>2+</sup>]<sub>i</sub> to 123 ± 36 nM. This response was inhibited by 55 ± 20% to 55 ± 22 nM by BBG 10<sup>-5</sup> M and 91 ± 2% to 9 ± 1 nM by BBG 10<sup>-4</sup> M (Fig. 4B).

To confirm the results obtained with BBG, we used a second inhibitor of P2X<sub>7</sub> receptors, A 438079, which is a highly selective competitive inhibitor of the P2X<sub>7</sub> receptor that does not react with other P2 receptors. In Mg<sup>2+</sup>-free buffer, A
Effect of Inhibition of P2X7 Receptors on BzATP-Stimulated Protein Secretion

To ensure that peroxidase secretion stimulated with BzATP was also P2X7 receptor mediated, the acini were preincubated for 15 minutes with BBG (10⁻⁷–10⁻⁵ M) before the addition of BzATP (10⁻⁴ M) for 40 minutes in the absence of extracellular Mg²⁺. Peroxidase secretion was then measured. BzATP significantly increased secretion to 1.2 ± 0.06-fold times basal. As shown in Figure 6, BBG inhibited BzATP-stimulated secretion in a concentration-dependent manner, similar to the effects seen on [Ca²⁺]ᵢ. Secretion was inhibited 36% ± 30% at BBG 10⁻⁷ M to 1.16 ± 0.06 and significantly inhibited 59% ± 10% and 86% ± 6% to 1.1 ± 0.01-fold and 1.0 ± 0.02-fold times basal at BBG 10⁻⁶ and 10⁻⁵ M, respectively. These data indicate that BzATP is activating the P2X7 purinergic receptor to stimulate protein secretion.

Effect of P2X7 Receptors on Activation of ERK 1/2

We previously showed that ERK 1/2 (also known as p42/p44 MAPK) was activated by muscarinic, α₁-adrenergic, and EGF receptors in the lacrimal gland.⁵,⁶,¹⁵ This activation attenuates agonist-stimulated protein secretion. Because P2X₇ receptors stimulate protein secretion, we investigated the effects of P2X₇ receptors on lacrimal gland ERK 1/2 activation. Acini were incubated with BzATP (10⁻⁷ and 10⁻⁴ M) or the cholinergic agonist BzATP 10⁻⁵ and 10⁻⁴ M in the presence or absence of Mg²⁺. BzATP in the presence of Mg²⁺ significantly increased protein secretion to 1.2 ± 0.06- and 1.2 ± 0.05-fold times basal at 10⁻⁵ and 10⁻⁴ M, respectively (Fig. 5A). This is in comparison to the response of 1.4 ± 0.1-fold times basal seen in the presence of the cholinergic agonist Cch (10⁻⁴ M), a well-known stimulus of lacrimal gland protein secretion. In the absence of Mg²⁺, protein secretion did not change with the addition of BzATP 10⁻⁵ M but was significantly increased at BzATP 10⁻⁴ M to 1.2 ± 0.07-fold times basal (Fig. 5B). There was also no difference between the basal values of protein secretion in the presence or absence of Mg²⁺ (13.1% ± 6% in the presence of Mg²⁺ and 13.7% ± 6% in the absence of Mg²⁺; data not shown). These experiments demonstrate that activation of P2X₇ receptors stimulates protein secretion.

Effect of Activation of P2X₇ Receptors on Protein Secretion

Because the lacrimal gland secretes the majority of the aqueous portion of the tear film, we determined the effect of activation of the P2X₇ receptor on lacrimal gland protein secretion. Acini were isolated and incubated with the P2X₇ receptor-specific agonist A 438079 (10⁻⁷–10⁻⁴ M) for 40 minutes (A) in the presence of extracellular Mg²⁺ and (B) in the absence of extracellular Mg²⁺. Peroxidase was then measured. Values are mean ± SE from three independent experiments. *Significant difference from basal alone.

438079 (10⁻⁷–10⁻⁴ M) inhibited BzATP-stimulated [Ca²⁺]ᵢ, in a concentration-dependent manner, with A 438079 10⁻⁴ M causing complete inhibition of this response (Fig. 4C). The peak increase in [Ca²⁺]ᵢ, stimulated by BzATP 10⁻⁵ M in the absence of Mg²⁺ was 95 ± 22 nM, which was inhibited by 25 ± 10, 46 ± 23, 80 ± 10, and 88 ± 8% to 77 ± 24, 66 ± 38, 19 ± 12, and 13 ± 10 nM at 10⁻⁷, 10⁻⁶, 10⁻⁵, and 10⁻⁴ M A 438079, respectively. To ensure that A 438079 (10⁻⁷ M), which completely inhibited the BzATP response, was not toxic to the acini, Cch (10⁻⁴ M), an agonist known to increase [Ca²⁺]ᵢ, in the lacrimal gland, was added after BzATP. As shown in Figure 4C, Cch increased [Ca²⁺]ᵢ, to 225 nM despite the fact that the cells did not respond to BzATP. Both inhibitors block BzATP-stimulated [Ca²⁺]ᵢ, indicating that BzATP activates the P2X₇ receptor in the lacrimal gland to increase [Ca²⁺]ᵢ.

**Figure 5.** Effect of activation of P2X₇ purinergic receptors on protein secretion. Rat lacrimal gland acini were incubated with BzATP or Cch (10⁻⁴ M) for 40 minutes (A) in the presence of extracellular Mg²⁺ and (B) in the absence of extracellular Mg²⁺. Peroxidase was then measured. Values are mean ± SE from three independent experiments. *Significant difference from basal alone.

**Figure 6.** Effect of inhibition of P2X₇ purinergic receptors on BzATP-stimulated protein secretion. Rat lacrimal gland acini were preincubated with BzATP for 15 minutes with BBG (10⁻⁷–10⁻⁵ M) before the addition of BzATP (10⁻⁴ M) for 40 minutes in the absence of Mg²⁺. Peroxidase was then measured, and percentage of response from basal was calculated. Values are mean ± SE from four independent experiments. *Significant difference from BzATP alone.
agonist Cch \((10^{-5} \text{ M})\) for 10 minutes either in the presence or absence of extracellular \(\text{Mg}^{2+}\). The amount of phosphorylated ERK 1/2 was then determined. BzATP significantly increased the phosphorylated ERK 1/2 by \(1.3 \pm 0.05\)-fold times basal. This increase was significantly inhibited by \(69\% \pm 23\%\), \(67\% \pm 23\%\), and \(100\% \pm 0\%\) to \(1.1 \pm 0.3\)-fold, \(1.0 \pm 0.2\)-fold, and \(0.9 \pm 0.3\)-fold times basal by BBG at \(10^{-7}, 10^{-6}\), and \(10^{-5}\) M, respectively (Fig. 8).

**Discussion**

In the present study, we demonstrate that P2X7 purinergic receptors are present and functional in the lacrimal gland. P2X7 receptors were detected by both immunofluorescence and Western blot analysis. The receptors were functional P2X7 receptors because BzATP-induced Ca\(^{2+}\) response was increased in the absence of extracellular \(\text{Mg}^{2+}\) and inhibited by two specific antagonists, BBG and A 438079. Activation of P2X7 receptors not only increased intracellular Ca\(^{2+}\) but stimulated protein secretion and ERK activity. Thus the lacrimal gland contains typical P2X7 receptors.

P2X7 purinergic receptors have been identified in salivary glands\(^{16}\) and implicated in their secretion from salivary glands.\(^{17}\) Interestingly, ATP was shown to inhibit cholinergic-agonist induced secretion, which did not occur in salivary glands from P2X7 knockout mice.\(^{17}\) This implies that ATP modulates the response of salivary glands. Because cholinergic...
agonists are major stimuli of lacrimal gland protein secretion, it would be of interest to determine whether activation of P2X7 purinergic receptors has similar effects.

It is well established that the effects of P2X7 purinergic receptors are intensified in the absence of extracellular Mg2+. This was demonstrated in the lacrimal gland when removal of Mg2+ from the buffer increased the rise in [Ca2+]i, stimulated by BzATP. However, removal of Mg2+ from the buffer did not increase the amount of peroxidase secretion, and, in fact, secretion was unchanged between the two conditions. The fusion of secretory granules and the release of their components into the lumen is the end point of a series of complicated processes. In contrast, the rise in [Ca2+]i, because of the activation of P2X7 receptors, occurs soon after activation of the receptor. It is possible that Mg2+ is essential for a step occurring distal to the increase in [Ca2+]i, and before exocytosis. In support of this, it is known that several mechanisms leading to exocytosis involve ATP hydrolysis, which is dependent on Mg2+. In the lacrimal gland, these mechanisms include actin reorganization at the apical membrane and association with nonmuscle myosin II, which occurs on cholinergic agonist stimulation.

The interesting Ca2+ response in the presence of BzATP 10−5 M (Fig. 3C) occurred often, though not every time (6 of 9 rats). This occurred in the three experiments shown in Figure 3A and the three experiments shown in Figure 4A, but not in the three experiments shown in Figure 4C. We have observed that there is heterogeneity in the [Ca2+]i response in that though all acini respond to BzATP, they do so at different rates. Some acini respond immediately to the stimulus, but other acini respond at a later time. We do not see this at higher concentrations of BzATP. Li et al. demonstrated similar changes in [Ca2+]i, in response to BzATP in human cervical cells. They established that the initial Ca2+ peak was attributed to the opening of the pores on the apical membranes and that the delayed response was attributed to the opening of the pores in the basolateral membranes. Because P2X7 receptors are also present on apical and basolateral membranes of acinar and duct cells, this could also occur in the lacrimal gland.

In the lacrimal gland, it is not known from where the ATP originates to stimulate P2X7 purinergic receptors. ATP can be released together with neurotransmitters from nerves, constitutively from many cells types, or as a result of a variety of stimuli, including mechanical stimuli, cell swelling, and inflammatory stimuli. In the lacrimal gland, there are three major cell types, acinar, ductal, and myoepithelial cells. Under normal conditions, stimuli from the external environment can activate the parasympathetic and sympathetic nerves in the lacrimal gland to release their neurotransmitters. This activation can cause the rapid, short-term release of ATP from sympathetic nerve terminals, myoepithelial cells in response to cholinergic agonist-induced contraction, or acinar cells in response to activation of muscarinic or α1-adrenergic receptors. The released ATP can then act in an autocrine or a paracrine manner, binding to the P2X7 receptors located on lacrimal gland cells.

It is possible that with the inflammation that develops with aging and in the disease progression of Sjögren syndrome, there is a prolonged presence of ATP either from an increase in the release from the lymphocytes that infiltrate the gland, a decrease in the extracellular enzymes that break down ATP, or a decrease in the adenosine P1 receptors that can be protective. The ATP could cause a prolonged activation of the P2X7 receptors to induce pore formation to cause acinar cell death. Thus the lacrimal gland could be a target of inflammation-induced activation of P2X7 receptors, leading to disease pathogenesis, as has already been proposed for diabetes, lupus, and Alzheimer’s disease.

In this study, we have focused exclusively on the P2X7 purinergic receptors. ATP can be converted to ADP, AMP, and adenosine, all which bind to other types of purinergic receptors. It is known that P1 receptors are present in the rabbit lacrimal gland, and preliminary evidence indicates that all the P2X receptors with the exception of the P2X5 receptor are present in the rat lacrimal gland. Thus purinergic receptors could play a significant role in the normal function of the lacrimal gland.

In conclusion, this study demonstrated that P2X7 receptors are present in the lacrimal gland. These receptors are functional because activation leads to an increase in [Ca2+]i, protein secretion, and ERK 1/2 activation. These receptors may play a significant role in the lacrimal gland in health and disease.

References